Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Ruxolitinib with or without Abatacept for the Prevention of Graft Versus Host Disease and Cytokine Release Syndrome after T-cell Haploidentical Stem Cell Transplant in Patients with Hematologic Malignancies

Trial Status: active

This phase I trial tests the safety, best dose, and effectiveness of ruxolitinib with or without abatacept in preventing graft versus host disease (GVHD) and cytokine release syndrome (CRS) after a haploidentical stem cell transplant in patients with hematologic malignancies. A stem cell is a type of cell found in the blood or bone marrow that helps form more blood cells. A stem cell transplant uses stem cells from a healthy donor to replace the diseased bone marrow in the recipient. A haploidentical stem cell transplant is a transplant that uses a donor that is half matched. GVHD, a possible side effect of stem cell transplants, occurs when some of the cells from the donor attack the tissues of the transplant recipient. CRS, another possible side effect, is a systemic inflammatory reaction caused by the release of an excessive amount of cytokines that can cause symptoms such as fever, rapid heartbeat, low blood pressure and trouble breathing. Ruxolitinib is a Janus-associated kinase (JAK) inhibitor that works by blocking the signals of the cells involved with cell growth and spread and immune response. Abatacept is used to decrease the body's immune response against the donor cells. Ruxolitinib with or without abatacept may be safe, tolerable and/or effective in preventing GVHD and CRS after a haploidentical stem cell transplant in patients with hematologic malignancies.